Hot Topics in Pharmacogenetics of Age-Related Macular Degeneration.

Schwartz SG, Brantley MA, Kovach JL, Grzybowski A
Curr Pharm Des. 2017 23 (4): 547-550

PMID: 27928964 · DOI:10.2174/1381612822666161208114847

Age-related macular degeneration (AMD) is a leading cause of irreversible visual loss and is primarily treated with nutritional supplementation as well as with anti-vascular endothelial growth factor (VEGF) agents for certain patients with neovascular disease. AMD is a complex disease with both genetic and environmental risk factors. In addition, treatment outcomes from nutritional supplementation and anti-VEGF agents vary considerably. Therefore, it is reasonable to suspect that there may be pharmacogenetic influences on these treatments. Many series have reported individual associations with variants in complement factor H (CFH), age-related maculopathy susceptibility 2 (ARMS2), and other loci. However, at this time there are no validated associations. With respect to AMD, pharmacogenetics remains an intriguing area of research but is not helpful for routine clinical management.

Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

MeSH Terms (7)

Age Factors Angiogenesis Inhibitors Dietary Supplements Humans Macular Degeneration Pharmacogenetics Vascular Endothelial Growth Factors

Connections (1)

This publication is referenced by other Labnodes entities:

Links